Skip to main content
Clinical Trials/EUCTR2019-002239-27-ES
EUCTR2019-002239-27-ES
Active, not recruiting
Phase 1

Study on the relationship between periodontal disease and serum levels of ultrasensitive Reactive C-Protein and fibrinogen - PERIODONTITIS AND INFLAMMATORY MARKERS

Clinica Dental AndreuDental0 sites123 target enrollmentJuly 26, 2019

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Patients with a diagnosis of periodontitis: There is interdental LCI in two or more non-adjacent teeth, or two or more teeth have a vestibular LCI = 3 with a PD > 3 mm
Sponsor
Clinica Dental AndreuDental
Enrollment
123
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 26, 2019
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
Clinica Dental AndreuDental

Eligibility Criteria

Inclusion Criteria

  • Patients with a Probing Depth \> 3 mm in at least oneprobing site in two or more teeth
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 60
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 63

Exclusion Criteria

  • Patients who have total edentulism, have received periodontal treatment in the last year, there being a decrease in inflammatory activity, are pregnant or breastfeeding, given the
  • immunological tolerance during pregnancy, they are diagnosed of ulceronecrotizing gingivitis (NUG), being an acute process,
  • ulceronecrotizing periodontitis (NUP), being an acute process or diagnosed with HIV, due to the state of immunosuppression, recent
  • history of angina, myocardial infarction or CVA, since they suppose a confusion factor when elevating the serum levels of the biomarkers,
  • antecedents of acute inflammatory processes or recent traumatisms, suffer chronic ingestion of non\-steroidal anti\-inflammatory drugs
  • (NSAIDs) or glucocorticoids, decrease the immune and inflammatory response, have taken antibiotics in the last three months, since they decrease the inflammatory activity and therefore the serum levels of
  • biomarkers.

Outcomes

Primary Outcomes

Not specified

Similar Trials